Literature DB >> 6373219

[Treatment of Raynaud's syndrome with captopril].

G Trübestein, E Wigger, R Trübestein, M Ludwig, M Wilgalis, K O Stumpe.   

Abstract

Twenty patients with primary or secondary Raynaud's phenomenon were, after a 4-week treatment-free interval, given captopril ( Lopirin ) at a dosage of 25 mg three times daily for 84 days. Marked subjective improvement was reported by 14 patients. Digital-artery pressure, blood flow at rest and blood flow during reactive hyperaemia increased. Blood flow at rest increased significantly after cooling (10 degrees C for three minutes).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6373219     DOI: 10.1055/s-2008-1069287

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  4 in total

Review 1.  Pathogenesis and treatment of Raynaud's phenomenon.

Authors:  J D Coffman
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

2.  Subjective and objective assessment of enalapril in primary Raynaud's phenomenon.

Authors:  V F Challenor; D G Waller; R A Hayward; M J Griffin; O S Roath
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

Review 3.  Management of Raynaud's phenomenon. Focus on newer treatments.

Authors:  S Roath
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 4.  Angiotensin converting enzyme inhibitors in Raynaud's phenomenon.

Authors:  V F Challenor
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.